Subscribe to receive this FREE daily commentary directly in your email
[widget id=”text-22″]
Why Micron Fell and Faces An Even Steeper Decline – The Daily Rundown
Michael Kramer and the clients of Mott Capital own shares of CELG and AAPL
Technology Smash
The technology sector got hit pretty hard again, with the NASDAQ more than 1 percent at one point during the day. The good news is the index bounce along the uptrend.
Micron
There may not have been a tech stock hit harder today than Micron. The stock got some negative commentary out of Baird this morning, noting peak gross margins, while DRAM prices may be peaking, and an oversupply in NAND. I have talked about Micron and its low valuation over and over and over. We have spoken about Micron being a gross margin story. If gross margins are peaking and heading lower, then so too is this stock. I know we focus a lot on the technical charts and that is because there is so much emotion in the stock, so technicals matter a great deal. But the gross margins and fundamentals of the business have always been a source of concern for me. That has still not changed. The low valuation has also served as evidence of the skepticism in the stock by investors as well.
So the big questions is where does the stock go now? I do not think the selling is over. A bit of a turn around from my thoughts the other day, when I thought shares might rise. But if we focus on the short-term, at least through earnings, the stock could see prices around $42.
Apple
Apple fell hard too, but then again Apple has been up a bunch the last few weeks. I could see the stock falling to around $215, should the uptrend around $222 not hold.
AMD
Even AMD fell a bit today. Held support around $27.85. I’m done predicting where this thing goes. I can’t get it right. I have probably gotten it right 1 or 2 times out of my last ten attempts. I’m guessing, but that is what it feels like.
Biotech
These biotechs have also been slaughtered the last few days. The IBB is below support. I know. It had looked like it was heading to its 2015 highs. I still think it gets there. The break out seems like it may occur at a more measured pace. The uptrend is still solidly in place.
Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month
[youtube-feed feed=7]The charts on Celgene, Regeneron, Gilead, and Biogen still look solid. The only one I have a bit of concern over now is Gilead.
China
The Chinese e-commerce stocks Alibaba and JD have gotten crushed, and I still think they are heading lower. JD to $25.5 and Baba to $151.
Macro
Don’t forget the big jobs reports tomorrow. ADP today came in a lighter than expected. Tomorrow will be a big day for yields. A lighter Payroll number or higher unemployment rate could be reason enough for the Fed to hold off in a few weeks from raising rates again. Watch the ten-year tomorrow. It may be a big day.
That’s it!
-Mike
Subscriber Video’s
Michael Kramer is the Founder of Mott Capital and the creator of Reading the Markets.
2 Stocks To Consider If You Like Square
Big Biotech Breakout, Plus iPhone Super Cycle Maybe This Year!
Biotech And Semis Breaking Out?
FAANG’s Not Out Of The Woods But Getting Better
Verizon Nears Multiyear Break Out As 5G Data Speeds Near
The Dollar May Soon Wreak Havoc On Oil And Gold
Inflation Runs Rampant Only In Fantasyland And That Is Good For Stocks
Tesla May Be Going Higher Regardless Of The Bid
Why The S&P 500 May Rise To 3,500
Netflix Is Not Broken, Plus S&P May Rise To 3,000 Sooner Than You Think
[widget id=”text-23″]
Subscribe to receive this FREE daily commentary directly in your email
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.